TVGN and TVGNW Related Headlines

Go Back

May 28, 2026 12:45PM Tevogen pursues acquisitions targeting $100 million annual revenue
May 28, 2026 12:30PM Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
May 18, 2026 12:15PM Tevogen reports 51% reduction in operational losses for 2025
May 18, 2026 12:15PM Letter to Shareholders from CEO Dr. Ryan Saadi
Apr 27, 2026 11:50AM Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Mar 18, 2026 12:22PM Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Feb 27, 2026 02:20PM Tevogen signs letter of intent to evaluate CRO acquisition
Feb 27, 2026 02:20PM Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
Jan 30, 2026 03:00PM Tevogen Bio (TVGN) to Evaluate Potential One-Time Special Cash Dividend
Jan 30, 2026 03:00PM Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Jan 12, 2026 09:03AM Tevogen expands T cell therapy pipeline across viral and cancer indications
Jan 12, 2026 09:00AM Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
Nov 14, 2025 02:36PM Tevogen Bio posts 51% reduction in nine-month operating loss
Nov 14, 2025 02:32PM Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

TVGN and TVGNW Related Press Releases

Go Back

May 28, 2026 12:30PM Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
May 18, 2026 12:15PM Letter to Shareholders from CEO Dr. Ryan Saadi
Apr 27, 2026 11:50AM Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Mar 18, 2026 12:22PM Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Feb 27, 2026 02:20PM Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
Jan 30, 2026 03:00PM Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Jan 12, 2026 09:00AM Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
Nov 14, 2025 02:32PM Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

TVGN and TVGNW Related SEC Filings

Go Back